GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Inclusion Criteria: * Females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal. * Vaccination against Neisseria meningitidis and Streptococcus pneumoniae received at least 2 weeks prior to first dose of investigational product * Well-demarcated geographic atrophy (GA) due to AMD * Best-corrected visual acuity (BCVA) letter score of 35 letters (approx. 20/200 Snellen equivalent) or better on the ETDRS chart * Must have clear ocular media and adequate pupillary dilation in the study eye to permit high-quality fundus imaging Exclusion Criteria: * Clinically-significant abnormalities in medical history * A lack of full recovery from any infection for at least 14 days prior to the Study Drug administration * Chronic treatment with steroids, including topically or intravitreally administered * History or presence of diabetic retinopathy or diabetic macular edema (DME) * History or presence of a disease other than AMD that could affect vision or safety assessments * Prior treatment with another investigational drug, biological agent, or device * Other protocol-specified inclusion/exclusion criteria may apply